ArticlePatient preference and adherence2026
Burden of Treatment and Disease on People with Hemophilia: Global Real-World Survey.
Article in Patient preference and adherence, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed.
- Etranacogene dezaparvovec in people with hemophilia B and without adeno-associated virus serotype 5 neutralizing antibodies: a 4-year subgroup analysis of the Health Outcomes with Padua Gene; Evaluation in Hemophilia B (HOPE-B) trial.Research and practice in thrombosis and haemostasis · 2026Article
- A Delphi Consensus by Hematologists on the Burden of Treatment on Patients with Severe Hemophilia in Mexico.Journal of blood medicine · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Introduction: Although prophylactic treatments can reduce bleeding risk for people with hemophilia (PwH), burdens associated with treatment and physical and psychological symptoms may persist. Aim: To determine treatment and disease burden associated with hemophilia from a global perspective. Methods: This cross-sectional patient survey captured patient-reported outcomes, experiences and clinical data from PwH in eight countries between December 2023 and March 2024. Treatment burden was measured using the child/adult Hemophilia Treatment Experience Measure (Hemo-TEM), validated questionnaires covering five domains. Disease burden was measured using the Patient-Reported Outcomes Measurement Information System 29+2 version 2.1 (PROMIS-29+2)/PROMIS Parent Proxy, validated questionnaires comprising eight domains. Here we report data on treatment, physical and psychological burdens for people with moderate and severe hemophilia without inhibitors by treatment class: standard half-life and extended half-life factor replacement for hemophilia A (HA) and hemophilia B (HB), and non-factor therapy for HA. Results: Data from 495 PwH and parents/guardians of PwH were analyzed. Across the five Hemo-TEM domains, adults with HA experienced similar degrees of treatment burden regardless of treatment class, with comparable results observed for adults with HB. Around one-third of PwH experienced soreness (33% HA; 31% HB) and pain (31% HA; 26% HB) due to their current treatment at least sometimes, and one in five experienced some level of treatment bother. PROMIS-29+2 scores indicated that people with HA and HB experienced similar degrees of physical and psychological burden regardless of treatment class. Anxiety and worry were prevalent among PwH. Conclusion: PwH continue to experience treatment- and disease-related burdens. Managing hemophilia still requires a balance between bleed protection, quality of life and ease of treatment administration.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.